NNovo Nordisk Read More Novo Nordisk ZEUS Trial: No MACE Benefit, HR 0.992026-07-31 Novo Nordisk (NYSE:NVO) reported headline results from the phase 3 ZEUS cardiovascular outcomes trial of…